| Cas No.: | 1660963-42-7 |
| 名称: | N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-8-quinazolinyl]phenyl]-2-Propenamide |
| 别名: | CK101,CK-101,CK 101,RX518,RX-518,RX 518 |
| SMILES: | C1CN(CCO)CCN1C1=C(F)C(F)=C(NC2=NC3C(C4=CC(NC(C=C)=O)=CC=C4)=CC=CC=3C=N2)C=C1 |
| 分子式: | C29H28F2N6O2 |
| 分子量: | 530.6 |
| 纯度: | |
| 保存条件: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | |
| In Vivo: | |
| In Vitro: | |
| References: | RX518(CK-101) is an orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, and the L858R and exon 19 deletion (del 19) mutations, with potential antineoplastic activity. |
| Kinase Assay: | |
| Cell Assay: | |
| Animal Administration: | |
| References: |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
